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Abstract
Introduction and Aims. There are considerable challenges faced by people with a history of injecting drug use (PWID) in
Vietnam, including drug-related stigma and lack of access to healthcare. Seeking and utilising healthcare, as well as harm reduction
programs for PWID, are often hampered by drug-related stigma. This study aimed to examine the impacts of drug-related stigma on
access to care and utilisation of harm reduction programs among PWID in Vietnam. Design and Methods. A cross-sectional
study was conducted in two provinces in Vietnam, Phú Th and Vinh Phúc. The study participants completed the survey by using
Audio Computer-Assisted Self-Interview between late 2014 and early 2015. Linear multiple regression models and logistic regression
models were used to assess the relationship among drug-related stigma, access to care and utilisation of harm reduction programs,
including methadone maintenance treatment (MMT) and needle exchange programs (NEP). Results. A total of 900 PWID
participated in this study. Drug-related stigma was significantly associated with lower level of access to care, but not with utilisation
ofMMTorNEP.Older age was positively associated with higher levels of access to care. Levels of education were positively correlated
with access to care, as well as utilisation of MMT and NEP.Discussion and Conclusions. This study underscores the need for
future interventions to reduce drug-related stigma in society and in health-care settings to improve PWID’s utilisation of care services.
Special attention should be paid to younger PWID and those with lower levels of education. [Lan C-W, Lin C, Thanh DC, Li L.
Drug-related stigma and access to care among people who inject drugs in Vietnam. Drug Alcohol Rev 2017;00:000-000]
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Introduction
Globally, it is estimated that a total of 246 million people
used an illicit drug in 2013, a 3 million increase over the
previous year [1]. People who use drugs are one of the
populations most in need of healthcare services [2].
Primary care practitioners see a large volume of patients
and often conduct initial diagnosis before referral to a
specialist. Therefore, increased access to primary care
and treatment referrals have shown to notably reduce
the rate of infectious disease transmission among people
with ahistoryof injectingdruguse (PWID) [3].Additionally,
harm reduction programs also show promising results.
For instance, previous reviews have shown that
methadone maintenance treatment (MMT) minimises
HIV-related risk behaviours, reduces drug-related criminal
activities and improves social functioning among PWID
[4]. Moreover, needle exchange programs (NEPs) are
effective in reducing the borrowing and lending of used
syringes, thus reducing the incidence of blood-borne
diseases while serving as a gateway to engage difficult-
to-reach individuals in services [5]. However, these
programs continue to face challenges, such as discrimi-
nation against PWID, low coverage among PWID and
lack of law enforcement and community support [6].
As a result, PWID remain medically underserved and
lack access to essential healthcare services [7].
Stigma has been identified as an important barrier to
care for PWID, leading to poorer health outcomes [8].
PWID were less likely to receive a routine physical
examination than the general population [9]. Literature
showed that there was a pervasive stigma among PWID,
resulting in their avoidance of utilising NEP in the
community due to fear of recognition and stigma
associated with injection drug use [10]. Some PWID fear
that accepting the need for harm reduction programs will
lead to greater stigma associated with being labelled as a
‘drug addict’ [11]. Even when services are accessed,
stigma may also hinder provider–patient communication
and prevent individuals from disclosing their drug use
Chiao-Wen LanMPH, Graduate Student Researcher, Chunqing Lin PhD, Assistant Professor-in-Residence, Duong Cong Thanh PhD, Head of HIV/
AIDS Surveillance Unit, Li Li PhD, Professor-in-Residence. Correspondence toDr Li Li, PhDUCLA Semel Institute, Center for Community Health,
10920 Wilshire Boulevard, Suite 350, Los Angeles, CA 90024, USA. Tel: (310) 794-2446; Fax: (310) 794-8297; E-mail: lililili@ucla.edu
Received 3 February 2017; accepted for publication 3 July 2017.
© 2017 Australasian Professional Society on Alcohol and other Drugs
Drug and Alcohol Review (2017)
DOI: 10.1111/dar.12589
 d lcohol Review (March 2018), 37, 333–339
 /dar.12589
© 2017 Australasia  r f si l   l    
8 37 333–339]
R E V I E W
problems to healthcare providers, the very issue for which
they may need the greatest need of care [8], leading to
compromised diagnosis and treatment management
[12]. Stigma is commonly identified as possessing ‘an at-
tribute that is deeply discrediting’, and it marks the per-
son as different from the rest of the community or its
understanding of normalcy [13]. Study assessing stigma
falls broadly into two categories, perceived stigma and
internalised stigma [14]. Perceived stigma, also labelled
as felt stigma, refers to an individual’s expectations about
the probability that stigma will be enacted in different sit-
uations [15]. Internalised shame refers to an individual’s
acceptance of stigma as his or her own self-concept [15].
Internalised shame differs from perceived stigma in that
the latter is about one’s awareness of social norms and ex-
pectations that stigmawill be enacted, yet it does not nec-
essarily mean that an individual believes that it is justified.
There is a growing problem of injection drug use in
Vietnam [1,12]. Since the early 1990s, the Vietnamese
government publically designated drug use as a ‘social
evil’ to be eradicated through punitive means, resulting
inmany PWIDbeing forcefully detained in detoxification
centres for extendedperiods and leading to stigmatisation
of drug use [16]. Previous research has shown pervasive
stigmatisation and discrimination against PWID in
Vietnam [17]. A recent study on male PWID released
within the past 2 years from compulsory detainment at
detoxification centres found that persistent stigma and
discrimination hindered employment, increased partici-
pants’ social isolation and exacerbated their struggles
with addictions [18]. Literature showed that even MMT
patients in rural Vietnam perceived high levels of stigma,
which were associated with unemployment, mental
health disorders and HIV infection [19]. Drug-related
stigma is often layered on top of pre-existing stigma, such
asHIV stigma [14,17]. Studies showed that the persistent
drug-related stigmatisation layered with HIV stigma in
Vietnam prevented HIV-infected PWID from disclosing
their status and seeking help [17,18].
In response to the growing problem of injection drug
use in the country, the Vietnamese government launched
pilot harm reduction programs focusing on MMT and
NEP [20]. By 2012, 88% of the provinces and cities in
Vietnam had implemented NEP and 61 MMT clinics
provide treatment in 20 cities and provinces across the
country [21]. However, these programs are facing chal-
lenges, such as lack of adequate training for physicians
and the effects of stigma and discrimination [22]. While
the government of Vietnam has since moved from an
approach based mostly on law enforcement toward an
increasingly critical role for harm reduction since 2006
[22], stigma against PWID persists and continues to be
one of the major barriers that impede care and harm
reduction programs in the country [23]. Despite the
well-documented need for quality services among PWID
worldwide [6], there is a paucity of research addressing
the health effects of stigmatisation among PWID in
Vietnam. To fill the gaps and to mitigate barriers to
accessing services, this study aimed to understand how
drug-related stigma affects PWID’s access to care and
utilisation of harm reduction programs (i.e. MMT and
NEP) in Vietnam to inform future development of
targeted intervention strategies in the country.
Methods
Participants and recruitment
The study used cross-sectional baseline data from a
randomised controlled trial conducted in Phú Th and
Vinh Phúc Provinces of Vietnam. The purpose of the in-
tervention trail was to enhance the role of commune
health workers inHIV and drug use prevention and treat-
ment for PWID in Vietnam. Communes with 20 ormore
registered PWIDwere eligible to be included in this study
to ensure enough caseload at each commune, resulting in
a total of 60 communes randomly selected from Phú Th
and Vinh Phúc provinces. We recruited 15 PWID from
each of the 60 participating commune health centres
(CHCs). In Vietnam, service providers in the local CHCs
provide curative and preventive health services, such as
referrals for HIV testing, counselling and preventive edu-
cation to PWID in the community [24]. Recruitment in-
formation was communicated verbally and with printed
flyers posted in the local CHCs where PWID regularly
received health services. The flyer described the project
as a ‘Health Service Study’ and provided a phone number
so that potential participants could either call formore in-
formation ormeet with a project recruiter at the centre. A
project recruiter met with prospective PWID individually
to screen for eligibility. The project recruiters provided
full disclosure of the study procedures, explained the
study purpose, ensured voluntary participation, confi-
dentiality issues and potential risks and benefits following
a standardised script. The recruiters informed prospec-
tive participants about their right to withdraw at any time
during the research. To be included in the study, the
participants needed to: (i) be 18 years or older; (ii) have
a history of injection drug use; and (iii) reside in the study
area. The refusal rate was less than 5%. We collected
baseline data fromOctober 2014 toFebruary 2015. Ethical
approval was granted by the Institutional Review Boards at
University of California, Los Angeles, and the National
Institute of Hygiene and Epidemiology in Vietnam.
Data collection
Following informed consent, the participants completed
baseline survey by using Audio Computer-Assisted Self-
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Interview that allowed them to directly input their an-
swers to the pre-programmed computer database. Our
project staff were on standby to provide clarification or
instructions for using Audio Computer-Assisted Self-
Interview. This tool aimed to provide confidentiality
and reduce social desirability during the assessment.
The approximate duration of the survey was approxi-
mately 45 to 60 min. All participants received 80 000
Vietnam đ ng (equivalent to 4 USD) for their time and
participation.
Measures
During the survey, the PWID were asked for demo-
graphic information, including gender, age, educational
attainment, marital status and annual family income.
Additionally, use of harm reduction programs was
assessed by asking the participants two separate ques-
tions: ‘have you ever been under MMT’ and ‘have
you ever used NEP’. Responses were recorded as
‘yes’ or ‘no’. Several multi-item scales were used in
the study to measure access to care and drug-related
stigma. To achieve culturally appropriate translation,
the ‘forward–backward’ translation procedure was
utilised [25]. We worked with the Vietnam research
team to verify and ensure the accuracy of the question-
naire translation. Any mismatches were discussed until
agreement was reached. Finally, the provisional version
of the translated questionnaire was pilot tested in
Vietnam to assess the feasibility and clarity of the items
and response categories.
Access to care scale was adapted from an instrument
previously administered to people living with HIV in
Thailand [26]. The scale consisted of seven items cre-
ated into a single composite variable as a proxy for ac-
cess to care and was modified for cultural relevance in
this current study. Access to care is conceptualised as a
product of multiple factors, including not only the
availability of services but also knowledge, attitude,
skills and self-care practices [27]. PWID were asked
whether they believed the following statements applied
to them: (i) ‘you have regular visits to your doctors
or medical providers’; (ii) ‘if you get sick, you know
where to go to get treatment’; (iii) ‘if you need more
information about your illness, you know where to
get them’; (iv) ‘you know when to go for your regular
check-up when you are not sick’; (v) ‘you know how
to protect yourself from getting sick’; (vi) ‘you can talk
freely to your doctor and other medical providers about
your illness’; and (vii) ‘you take vitamins or supple-
ments regularly in order to stay healthy’. The responses
were recorded as 0 being ‘no’ and 1 being ‘yes’. A
summative composite score was created with higher
score indicating a higher level of access to care. The
scale had a Cronbach’s alpha of 0.72, supporting its in-
ternal consistency reliability.
Drug-related stigma was assessed by using a 17-item in-
strument, including two subscales: perceived stigma and
internalised shame. The Perceived Stigma of Addiction
Scale is an 8-item measure [28], adapted from the Per-
ceived Devaluation and Discrimination Questionnaire
to measure perceived stigma toward serious mental ill-
ness [29]. The Perceived Stigma of Addiction Scale mea-
sures stigma as perceived by substance users and has
been found to have adequate internal consistency
(α = 0.73). In this current study, the questionnaire asked
the participants to indicate the degree of their agreement
or disagreement with statements regarding feelings that
people sometimes have about drug use, such as ‘most
people think less of a person who has been in treatment
for substance use’. In addition to the first eight items in
the Perceived Stigma of Addiction Scale, the subscale
internalised shame was adapted for use with participants
reporting substance use problems from a measure of
internalised shame in people living with HIV/AIDS
[30]. For instance, the participants were asked the degree
they agreed with the statement, ‘your life is filled with
shame’. Table 1 presents the list of items in the drug-re-
lated stigma instrument. Response categories ranged from
(1) ‘strongly disagree’ to (5) ‘strongly agree’. A total score
was created to represent the sum of endorsed items,
scores ranged from 17 to 85, with higher score implying
a higher degree of drug-related stigma. The drug-related
stigma scale was internally consistent, Cronbach’s alpha,
α = 0.85.
Data analysis
We first examined the frequency distributions of
PWID demographics and other measures of interest.
We then calculated Pearson’s correlation coefficients
to examine the relationship among drug-related stigma,
access to care, use of MMT, NEP and continuous de-
mographic variables, such as age, family annual income
and years of education. We constructed linear multiple
regression models to assess the relationship between
drug-related stigma and access to care, simultaneously
controlling for the participants’ demographic character-
istics. Similarly, we carried out logistic regression
models to assess the relationship between drug-related
stigma and use of MMT and NEP, respectively, while
controlling for the same demographic variables. Re-
gression coefficient estimation and their significant
levels were reported for linear multiple regression
models; odds ratios and their P-value were presented
for logistic regression analyses. All analyses were per-
formed by using SAS software version 9.4 (SAS Insti-
tute, Cary, NC, USA).
Stigma and access to care among drug users
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Results
Sample characteristics
Table 2 presents the demographic characteristics and the
outcome measures of the respondents. A total of 900
PWID participated in this study; 97.9% were male with
a mean age of 36.8 years (SD = 8.0; ranged from 18 to
65 years), which was consistent with the demographics
of the PWID in Vietnam (95% male) [31]. The majority
(72.4%) of the participants weremarried or living asmar-
ried. The average annual family income was 77 130 782
Vietnam đ ng (equivalent to 3459 USD). Most partici-
pants (95.2%) received basic education, including 5 years
of primary education, 4 years of intermediate education
and 3 years of secondary education. Furthermore, the
mean scores of drug-related stigma and access to care were
58.5 (SD = 8.8) and 5.2 (SD = 1.5), respectively. More
than half of the participants reported possessing the
stigmatising beliefs listed in the stigma scale, with the ex-
ception of the item ‘you feel your life is worthless’ (44.1%
of the participants agreed to this statement), indicating
high levels of drug-related stigma among the participants.
At baseline, 16.9% (n = 152) of the PWID was HIV-
positive, of whom 83.9% were currently on antiretroviral
therapy. Twenty-nine and 20% of the PWID had ever
usedMMTandNET, respectively, while 27.4%was cur-
rently under MMT.
The correlation coefficients among demographic char-
acteristics, drug-related stigma, access to care,MMTand
NEP are shown in Table 3. Significant negative
correlations were observed among access to care and
drug-related stigma (r =0.14, P< 0.001). Positive cor-
relations with access to care were also found between age
and being married (r = 0.10, P = 0.004; r = 0.09,
P = 0.008, respectively). Previous utilisation of harm
reduction programs, that is, ever been under MMT and
NEP, was positively correlated with access to care
(r = 0.25, P < 0.001; r = 0.10, P = 0.002, respectively).
Family annual income was negatively correlated with
levels of drug-related stigma (r = 0.07, P = 0.027),
while years of education was positively correlated with it
(r = 0.11, P = 0.001). Years of education was positively
Table 2. Characteristics of study participants (N = 900)
Characteristics Count (%)
Gender
Male 881 97.9
Female 19 2.1
Age, years, Mean (SD) 36.8 8.0
18–30 211 25.6
31–35 171 20.7
36–40 159 19.3
41+ 284 34.4
Marital status
Married or living as married 652 72.4
Not married 248 27.6
Family annual income
(Vietnam đ ng), Mean (SD)
77 130 782 114 113 852
Less than 30 000 000 257 28.7
30 000 001–50 000 000 227 25.3
50 000 001–80 000 000 220 24.6
More than 80 000 000 192 21.4
Education, Mean (SD) 9.8 3.0
Less than primary education 42 4.7
Completed basic education 778 86.5
Greater than basic education 79 8.8
Harm reduction program usage
Ever used MMT 264 29.3
Ever used NEP 180 20.0
Ever used MMT and NEP 69 7.7
Access to care (M ± SD) 5.2 1.5
Drug-related stigma (M ± SD) 58.5 8.8
MMT,methadonemaintenance therapy;NEP, needle exchange
program.
Table 1. Items in drug-related stigma measure
Perceived drug-related stigma
1. Most people would willingly accept someone who has
been treated for substance use as a close friend (R).
2. Most people believe that someone who has been treated
for substance use is just as trustworthy as the average citi-
zens (R).
3. Most people would accept someone who has been treated
for substance use as a teacher of young children in a public
school (R).
4. Most people would hire someone who has been treated
for substance use to take care of their children (R).
5. Most people think less of a person who has been in treat-
ment for substance use.
6. Most employers will hire someone who has been treated
for substance use if he or she is qualified for the job (R).
7. Most employers will pass over the application of someone
who has been treated for substance use for another
applicant.
8. Most people would be willing to date someone how has
been treated for substance use (R).
Internalised drug-related shame
9. You are punished by evil1
10. Your life is tainted.
11. You are angry with yourself as a drug user.
12. You are a disgrace to the society.
13. Your life is filled with shame.
14. You fill guilty for being the source of disruption in the
family.
15. You feel your life is worthless.
16. You feel your reputation is lost.
17. If possible, you want to conceal your drug status for life.
1Self-stigmatisation as people consider drug-related stigma a
punishment for their behaviour.
Note. (R) indicated that the item was reversed coded.
C.-W. Lan et al.
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associated with having ever used MMT and NEP
(r = 0.15, P< 0.001; r = 0.09, P = 0.005). Ever been un-
der MMT was positively correlated to ever used NEP
(r = 0.10, P = 0.003).
Table 4 shows the regressionmodels examining factors
associated with access to care and utilisation of harm
reduction programs, including MMT and NEP.
Controlling for selected independent variables, higher
levels of drug-related stigma were associated with lower
levels of access to care [beta (β) = 0.026, P < 0.0001].
In addition, older age and more years of education were
positively associated with higher levels of access to care
(β = 0.020, P = 0.003; β = 0.035, P = 0.046, respec-
tively). Having ever used MMT or NEP was not associ-
ated with drug-related stigma. Those with more years of
education have higher odds of ever used MMT and
NEP (odds ratio = 1.13, P < 0.0001; odds ratio = 1.08,
P = 0.009, respectively).
Discussion
The findings of this study suggest that drug-related
stigma experienced by PWID could result in lower access
to care, leading to public health concerns. For instance,
failure to routinely seek preventive care can increase the
likelihood of using crisis treatment and care. Research
has documented that the barriers to treatment posted by
drug-related stigma are similar to ways in which these
stressors have been shown to deter treatment seeking
for mental illness and HIV/AIDS [32–34]. Moreover, it
is critical to note that the level of drug-related stigma per-
ceived by PWID has been shown to persist even when
drug use is reduced or ended, which may adversely affect
the long-term health of this population [29]. While the
study showed an association between drug-related stigma
and access to care, research on other stigmatised condi-
tions, such asHIV/AIDS andmental illness, suggests that
there are likely to be other negative consequences of
drug-related stigma for PWID [32,33]. The negative
consequences were related to compliance with medica-
tions, access to social welfare systems and drug use be-
haviours [34]. Even when stigma is not directly
experienced in healthcare settings, it can take a toll in
healthcare utilisation by discouraging people from seek-
ing services [34]. These results suggest that there may
be potential benefits of addressing drug-related stigma
in enhancing care access among PWID and deterring
the detrimental influence of stigmatisation on mental
and physical health stemming from exposure to chronic
Table 3. Correlation coefficients and significance levels among selected variables (N = 900)
1 2 3 4 5 6 7
1. Access to care
2. Age 0.10**
3. Married 0.09** 0.29**
4. Family annual income 0.04 0.08* 0.05
5. Years of education 0.02 0.22** 0.13** 0.03
6. MMT 0.25** 0.02 0.07* 0.02 0.15**
7. NEP 0.10** 0.01 0.06 0.01 0.09** 0.10**
8. Drug-related stigma 0.14** 0.06 0.04 0.07* 0.11** 0.02 0.02
*P < 0.05. **P < 0.01. MMT, methadone maintenance therapy; NEP, needle exchange program.
Table 4. Multiple regressions on access to care and logistic models of harm reduction program usage (N = 900)
Access to care MMT NEP
β P-value OR P-value OR P-value
Age 0.020 0.003 1.010 0.330 1.010 0.370
Married 0.201 0.093 0.746 0.086 0.770 0.173
Family annual income1 0.003 0.558 0.989 0.156 0.998 0.803
Years of education 0.035 0.046 1.130 <.0001 1.081 0. 009
Drug-related stigma 0.026 <0.0001 0.988 0.163 1.001 0.949
1Family annual income per 10,000,000 Vietnam đ ng for ease of interpreting coefficient.
Note. β = beta coefficient; MMT, methadone maintenance treatment; NEP, needle exchange program; OR, odds ratio.
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stress [35]. We also found that age was positively
associated with access to care. This finding could be in
part explained by the fact that older adults often have
increased healthcare needs than younger adults, making
accessing health care unavoidable to attend to their
needs. Similarly, a study conducted amongHIV-infected
PWID found that younger PWID were less likely to
receive antiretroviral therapy [36], suggesting that greater
effort should be made to engage young PWID in care
services early on.
In this study, drug-related stigma was associated with
access to care, but not with specific harm reduction
programs, such as MMT or NEP. The findings implied
that drug-related stigma was a critical factor for accessing
health care in non-drug-related settings where services
were provided to a wide range of populations. One
possible explanation was that the fear of confidentiality
prevented individuals with substance abuse problems
from entering and utilising primary care. On the other
hand, MMT and NEP provide services to individuals
with substance use problems specifically. As a result,
PWIDmay be less concerned about being treated or seen
differently from the rest of the clients at harm reduction
programs than at primary care facilities. Literature has
documented the benefits of altering healthcare delivery
paradigm from vertical/stand-alone projects (MMT
facilities only provide MMT services) to
diagonal/integrative model to address the unmet needs
of drug users for medical services [37]. Additionally, the
persistent drug-related stigma experienced by PWID
may discourage them from obtaining healthcare due to
fear of poor treatment by healthcare providers or fear of
getting into troubles with the authorities [16]. Conse-
quently, those who experience more stigma and discrim-
inationmay bemore likely to drop out of treatment [8]. A
recent systematic review that found a small body of re-
search that has empirically evaluated interventions
targeting drug-related stigma has demonstrated efficacy
in reducing drug-related stigma in several Western coun-
tries [9]. A study conducted in the USA by Luoma et al.
found that group-based Acceptance and Commitment
Therapy resulted in significantly decreased internalised
stigma and shame among people with substance use dis-
orders [38]. There could be potential benefits in adopting
and pilot testing similar model strategies to reduce drug-
related stigma in order to enhance access to and
utilisation of harm reduction programs among PWID in
other non-Western countries, including Vietnam.
The findings suggested that levels of education were
positively correlated with access to care, as well as usage
of MMT and NEP. Research on education and access
to health care suggested that higher levels of education
were associated with an increase in the use of preventive
care [39]. One possible explanation was that more edu-
cated individuals were better informed about healthcare
and had a greater ability to understand health informa-
tion. PWID with lower levels of education may be less
aware of the care benefits and less likely to seek care.
Therefore, efforts should be directed to make health
and harm reduction programs more accessible to PWID
with low levels of education, such as using pictures to
improve health communication, designing media with
simpler illustrations and communicating in simpler
words. Furthermore, literature has shown that activities
of peer outreach workers were effective in engaging
PWID and increasing access to health interventions in
Vietnam [40]; targeted efforts should bemade to increase
the participation inMMT among PWID with lower level
of education. Further research is needed to assess the
feasibility and acceptability of targeted harm reduction
programs for PWID with low education attainment in
Vietnam.
Limitations
Several study limitations should be noted. First, this
study utilised a cross-sectional design, so we can not
make causality inference or investigate the continuity of
MMT/NEP service use. Second, these data were based
on self-reports, which were subject to social desirability
bias. Third, the study was conducted in two provinces
of Vietnam that may limit the generalisability of the re-
sults documented. Additionally, the study participants
were recruited from CHCs; thus, the results may not be
generalisable to individuals who did not receive service
from CHC. Moreover, future study would usefully in-
clude drug-related stigma measures that are specific to
healthcare settings. Future study would benefit from
considering other confounders, such as PWID’s knowl-
edge and perceived benefits of MMT and NEP, access
to information and peer educators, which were not con-
sidered in this study.
Conclusion
Drug-related stigma continues to be a major obstacle for
PWID to access care in Vietnam. Stigmatisation may
marginalise PWID’s access to services, thus reducing ca-
pacity for risk reduction. Interventionists should consider
developing strategies to address drug-related stigma to
improve PWID’s utilisation of care services. Addition-
ally, special efforts should be directed to younger PWID
and those with lower levels of education.
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